论文部分内容阅读
预防或治疗化疗药物对肿瘤病人肝脏损害的问题，为改善化疗期生活质量的重要内含之一。本文首次报道了７０例（化疗２０２例次）实体瘤化疗期并用肝得健６００ｍｇ／次，３次／日，平均服药３周，与５５例（化疗２３１例次）单用化疗者比较。肝功能损害率各为１６．８％（３４／２０２）和４４．２％（１０２／２３１）（Ｐ＜０．００００１，χ２＝３６．０８８９）。ＷＨＯⅢ／Ⅳ度肝功损害各为２．５％（５／２０２）与１３．９％（３２／２３１），（Ｐ＜０．０００１，χ２＝１６．３８３０）；４周后肝功尚未恢复各为２．９７％（６／２０２）与１７．７４％（４１／２３１）（Ｐ＜０．０００１，χ２＝２２．８２０６）。故本研究结果显示：肝得健在预防化疗药物所致的肝脏损害方面有显著疗效
Prevention or treatment of chemotherapy drugs on the liver of patients with tumor damage, to improve the quality of life during chemotherapy one of the important implications. The first report of 70 cases (202 cases of chemotherapy) solid tumor chemotherapy and Liver Health 600mg / time, 3 times / day, taking an average of 3 weeks, compared with 55 cases (231 cases of chemotherapy) alone chemotherapy. The rates of liver dysfunction were 16.8% (34/202) and 44.2% (102/231), respectively (P <0.00001, χ2 = 36.0889). WHO Ⅲ / Ⅳ degrees of liver damage were 2.5% (5/202) and 13.9% (32/231), respectively (P <0.0001, χ2 = 16.3830); liver function did not recover after 4 weeks Were 2.97% (6/202) and 17.74% (41/231) (P <0.0001, χ2 = 22.8206). Therefore, the results of this study show that: Liver Health in the prevention of chemotherapy-induced liver damage have a significant effect